These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34358517)

  • 1. mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma.
    Lee HJ; Shin DH; Song JS; Park JY; Kim SY; Hwang CS; Na JY; Lee JH; Kim JY; Park SW; Sol MY
    Am J Pathol; 2021 Nov; 191(11):1999-2008. PubMed ID: 34358517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
    Guo X; Li R; Bai Q; Jiang S; Wang H
    J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment.
    Hwang C; Kang YK; Kim JY; Shin SH; Park JY; Song JS; Kim SY; Jung SJ; Lee JH; Na JY; Shin DH; Kim JY; Park SW; Lee HJ
    Am J Pathol; 2024 Jul; 194(7):1306-1316. PubMed ID: 38588851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
    Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma.
    Fang R; Wang X; Xia Q; Zhao M; Zhang H; Wang X; Ye S; Cheng K; Liang Y; Cheng Y; Gu Y; Rao Q
    Oncogene; 2021 May; 40(18):3303-3317. PubMed ID: 33846569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.
    Fang Y; Bao W; Rao Q; Wang X; Xia Q; Shen Q; Zhou X; Yao B
    Mol Med Rep; 2017 Sep; 16(3):2721-2725. PubMed ID: 28713889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
    BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
    Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
    J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.
    Jeong SU; Hwang HS; Park JM; Yoon SY; Shin SJ; Go H; Lee JL; Jeong G; Cho YM
    Cancer Res Treat; 2023 Jan; 55(1):231-244. PubMed ID: 35240013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
    Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
    J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
    Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
    Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
    Kuroda N; Kawada C; Tamura K; Hiroi M; Hes O; Michal M; Wada Y; Inoue K; Ohara M; Mizuno K; Shuin T; Lee GH
    Med Mol Morphol; 2011 Mar; 44(1):46-51. PubMed ID: 21424937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation.
    Thorner PS; Shago M; Marrano P; Shaikh F; Somers GR
    Pathol Res Pract; 2016 Oct; 212(10):937-942. PubMed ID: 27450657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
    Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
    Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors.
    Rua Fernández OR; Escala Cornejo R; Navarro Martín M; García Muñoz M; Antunez Plaza P; García Dominguez AR; Cruz Hernández JJ
    Urology; 2018 Jul; 117():41-43. PubMed ID: 29702156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.